AesRx, a US-based biopharmaceutical company backed by MedImmune Ventures (wholly-owned corporate venturing fund within the AstraZeneca Group, founded in 2002 for investing in emerging healthcare), has raised $1.36m convertible debt out of a $1.53m offering, according to a 9 May regulatory filing.

AesRX is also backed by Fidelity Biosciences, a venture capital division of mututal fund manager Fidelity Investments.

Prior to founding AesRX, the firm’s chief executive, Stephen Seiler, headed the pharmaceutical industry investment banking group for Paribas Capital Markets, went on to work at pharmaceutical company Elan Corporation, and has restructured several biotechnology companies.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?